Journal of dermatological science
-
Randomized Controlled Trial Multicenter Study
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Brodalumab (KHK4827 or AMG 827) is a human monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the biological activities of IL-17A, IL-17F, IL-17A/F, and IL-17E also known as IL-25. A 12-week phase 2 trial in the USA, Europe, and other countries showed the good efficacy of brodalumab in treating patients with moderate to severe plaque psoriasis. However, with the exception of a phase 1 study, a clinical trial of brodalumab in psoriasis has not been undertaken in Japan. ⋯ The rapid, robust efficacy of brodalumab and its favorable safety profile shown in the current study confirm previous studies conducted in Caucasian people, further warranting the use of brodalumab as a new treatment option for plaque psoriasis.
-
Randomized Controlled Trial Multicenter Study
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Ustekinumab has been evaluated in Caucasian patients with psoriasis, but no studies have been conducted in Asian patients. ⋯ Treatment with subcutaneous ustekinumab 45mg offers a favorable benefit/risk profile for Taiwanese and Korean patients with moderate-to-severe psoriasis. The efficacy and safety profile is consistent with the global phase III studies of ustekinumab in psoriasis.
-
Randomized Controlled Trial Multicenter Study
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
A clinical trial of infliximab in psoriasis has not yet been performed in Asian populations, although infliximab has been approved for the indications of psoriatic arthritis and plaque psoriasis in the US and the EU. ⋯ Infliximab could provide a sustained improvement effect on skin and joint symptoms, and accordingly contributed to a sustained improvement in the QOL of patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Infliximab was generally well tolerated in most patients. These results corresponded with the results of the trials in the US and the EU.